Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Carnival Corp (CCL) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

Carnival (CCL) trades at $26.83, up 0.41% on the day, with a bullish fundamental recovery story supported by three consecutive quarterly EPS beats. The stock shows a bearish technical signal but strong valuation metrics including a P/E of 12.09 and ROE of 26.72%. Recent news highlights the launch of the new Carnival Destiny ship and a declared $0.15 dividend, reinforcing growth initiatives.

Outlook remains positive with analyst consensus at Buy (59.57%) and a $35 price target, though risks include geopolitical tensions impacting oil prices and European demand softness. Net income margin improved to 11.24% in 2025, with debt reduction trends supporting financial health. The stock offers upside potential if operational momentum and cost controls persist amid industry headwinds.